Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease.
Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease.
复制标题
DOI：
10.2991/chi.d.190316.002
复制
发表时间：
2019-03
影响因子：
--
通讯作者：
Youngster I
中科院分区：
文献类型：
--
作者：
Shouval R;Geva M;Nagler A;Youngster I
人们对胃肠道 (GI) 微生物群与免疫系统之间双向关系的日益了解，为移植物抗宿主病 (GVHD) 的治疗开辟了新途径。粪便微生物群移植 (FMT) 是将粪便从供体转移到受者体内，受者体内的胃肠道微生物群受到干扰，从而导致疾病。我们回顾了进行 FMT 治疗急性 GVHD 的基本原理，并总结了异基因造血干细胞移植 (HSCT) 受者中该手术的安全性和有效性的数据。总体而言，FMT 是治疗和预防 HSCT 相关并发症的一种有前景的策略。然而，应谨慎行事，因为 HSCT 受者的免疫功能高度抑制，随着 FMT 应用的增加，可能会出现意外的感染性不良事件。
The growing understanding of the bidirectional relationship between the gastrointestinal (GI) microbiome and the immune system has opened up new avenues for treatment of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is the transfer of stool from a donor to a recipient who harbors a perturbed GI microbiome resulting in disease. We review the rationale for performing FMT for the treatment of acute GVHD, and summarize data on the safety and efficacy of the procedure among allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Overall, FMT is a promising strategy in treating and preventing HSCT-related complications. However, caution should be exerted as HSCT recipients are highly immunosuppressed and unanticipated infectious adverse events may appear with the increasing application of FMT.